Viatris (VTRS) Competitors

Viatris (NASDAQ:VTRS) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Which has more risk & volatility, VTRS or TAK?

Viatris has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.

Is VTRS or TAK a better dividend stock?

Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 3.6%. Takeda Pharmaceutical pays an annual dividend of $0.24 per share and has a dividend yield of 1.7%. Viatris pays out -64.9% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 41.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Viatris is clearly the better dividend stock, given its higher yield and lower payout ratio.

Which has preferable earnings & valuation, VTRS or TAK?

Takeda Pharmaceutical has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$15.43B	1.02	$54.70M	-$0.74	-17.84
Takeda Pharmaceutical	$28.20B	1.56	$994.06M	$0.58	23.90

Do analysts recommend VTRS or TAK?

Viatris presently has a consensus target price of $13.33, indicating a potential upside of 1.01%. Given Viatris' stronger consensus rating and higher probable upside, equities analysts plainly believe Viatris is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the media refer more to VTRS or TAK?

In the previous week, Viatris had 3 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 5 mentions for Viatris and 2 mentions for Takeda Pharmaceutical. Viatris' average media sentiment score of 0.67 beat Takeda Pharmaceutical's score of 0.56 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in VTRS or TAK?

Takeda Pharmaceutical received 78 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 56.82% of users gave Takeda Pharmaceutical an outperform vote while only 36.07% of users gave Viatris an outperform vote.

Company	Underperform	Outperform
Viatris	Outperform Votes 22 36.07%	Underperform Votes 39 63.93%
Takeda Pharmaceutical	Outperform Votes 100 56.82%	Underperform Votes 76 43.18%

Do insiders and institutionals have more ownership in VTRS or TAK?

79.9% of Viatris shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 0.1% of Viatris shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Is VTRS or TAK more profitable?

Takeda Pharmaceutical has a net margin of 6.49% compared to Viatris' net margin of -5.87%. Viatris' return on equity of 16.46% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-5.87%	16.46%	7.09%
Takeda Pharmaceutical	6.49%	10.00%	4.78%

Summary

Viatris beats Takeda Pharmaceutical on 12 of the 20 factors compared between the two stocks.